A mixture of: α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-hydroxypoly(oxyethylene); α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyloxypoly(oxyethylene)

Endpoint summary

Description of key information

Valid acute toxicity studies with the test substance are available. In a study conducted according to OECD guideline 401 the oral LD 50 was greater than 5000 mg/kg bw (SD-rat, Ciba-Geigy Ltd 1984a). In a study conducted according to OECD guideline 403 the inhalative LD 50 was greater than 5.8 mg/l (aerosol,SD-rat, Ciba-Geigy Ltd 1988). In a study conducted according to OECD guideline 402 the dermal LD 50 was greater than 2000 mg/kg bw (SD-rat, Ciba-Geigy Ltd 1984b).

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating dose

Value:

2 000 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating conc.

Value:

5 800 mg/m³ air

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating dose

Value:

2 000 mg/kg bw

Additional information

Groups of 5 male and 5 female SD-rats were given 5000 mg/kg bw test article by oral gavage according to OECD 401 with a subsequent 14 day recovery period (Ciba-Geigy Ltd 1984a). Dyspnea, exophthalmia, ruffled fur, abnormal body position, chromodacryorrhea, ventral body position, diarrhea, and tonic clonic convulsions were seen. In both groups animals recovered within 10 days and no mortality occurred. Thus, the LD50 is greater than 5000 mg/kg bw.

Rats of both sexes were exposed to 5.8 mg/l test article for 4 h according to OECD 403 (1981) as vapour with a subsequent 14 day recovery period (Ciba-Geigy Ltd 1988). Ruffled fur, dyspnea, hunched posture and reduced spontaneous activity were seen. All animals recovered within 6 days and no mortality occurred. Thus, the LC50 was above 5.8 mg/l for both sexes.

After dermal application of 2000 mg/kg bw of test article to SD-rats of both sexes for 24 h under semi-occlusive conditions according to OECD 402 (1984), rats were observed for a 14 day recovery period (Ciba-Geigy Ltd 1984b). Dyspnoea, exophthalmia, ruffled fur and abnormal body positions were seen. All animals recovered within 11 days and no mortality occurred. Thus, the LD50 was above 2000 mg/kg bw for both sexes.

Justification for classification or non-classification

Dangerous Substance Directive (67/548/EEC)

The available studies are considered reliable and suitable for classification purposes under 67/548/EEC. As a result the substance was not considered to be classified for acute oral or dermal or inhalation toxicity according to Annex I of Directive 67/548/EEC, as amended for the 28th time in Directive 2001/59/EC.

Classification, Labelling, and Packaging Regulation (EC) No. 1272/2008

The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. As a result the substance was not considered to be classified for acute oral or dermal or inhalation toxicity under Regulation (EC) No. 1272/2008, as amended for the third time in Directive ( EC 618/2012).